Aug 8, 2021 01:59AM obsolete wrote:
Blessings, congrats on almost reaching your 10-year mark, but sorry you're back. It's common for papillary lesions to recur in peripheral areas of breasts, so please don't knock yourself. You may also wish to read the "Papillary Carcinoma" thread for more information. Best Wishes!
"Due to the high upgrade rate of atypical papillary lesions to carcinoma (42%), EXCISION of ALL atypical papillary lesions with wide excision margin is recommended for cases with pathologic diagnosis of atypical papillary lesion on core-needle biopsy."
"DIFFERENTIAL CD133 EXPRESSION DISTINGUISHES MALIGNANT..."
Chih-Hung Lin et al. Virchows Arch. 2015 Feb."
"CD133 expression in papillary carcinomas was significantly lower than that in benign and atypical papillomas (p < 0.001). CD133 expression in invasive carcinoma NST was also significantly higher than that in papillary carcinomas. Our data suggests that absence of expression of CD133 can be a useful marker in the differential diagnosis between malignant papillary lesions and their benign or atypical mimics. The characteristic loss of CD133 expression in papillary carcinomas of the breast also indicates that these lesions are distinct from other types of breast cancer."
Paul E. Goss claims:
"More than 50% of breast cancer recurrences and deaths occur five or more years after completing tamoxifen treatment."
-- Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer completing 5 years of tamoxifen. J Clin Oncol. 2008